A Goldhirsch Selected Research

Breast Neoplasms (Breast Cancer)

08/2008	Anthracyclines for gestational breast cancer: course and outcome of pregnancy.
07/2008	Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
01/2008	Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.
01/2008	Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.
12/2007	Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination.
09/2007	Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
05/2007	Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
04/2007	CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.
01/2007	Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
10/2006	Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer.
09/2006	A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer.
05/2006	Breast cancer vaccines: a clinical reality or fairy tale?
02/2006	Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.
02/2006	Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
10/2005	Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab.
10/2005	Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer.
09/2005	Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery.
05/2005	Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
12/2004	Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
11/2004	Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer.
04/2004	Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.
02/2004	Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean).
02/2004	Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG).
10/2003	Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase.
08/2003	Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation.
06/2002	Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.
01/2002	Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.
11/2001	Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.
11/2001	Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
10/2001	Mosaic tumour blood vessels and high-dose chemotherapy for breast cancer.
07/2001	Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.
03/2001	High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
01/2001	Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study.
08/2000	Taxanes as adjuvant for breast cancer.
08/2000	Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors.
08/2000	Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
06/2000	Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality.
05/2000	Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
05/2000	Unexpected right phrenic nerve injury during 5-fluorouracil continuous infusion plus cisplatin and vinorelbine in breast cancer patients.
04/2000	Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
02/2000	Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
01/2000	Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required?
01/2000	Parathyroid hormone-related protein in metastatic breast cancer induced hypercalcemia: a case report.

Articles by Research Topic

Disease

43	Breast Neoplasms (Breast Cancer) 08/2008 - 01/2000
4	Neoplasms (Cancer) 01/2007 - 08/2000
2	Carcinoma (Carcinomatosis) 05/2004 - 03/2000
2	Small Cell Carcinoma 02/2001 - 07/2000
1	Necrosis 01/2008
1	Purpura 01/2007
1	Osteonecrosis (Kienbock's Disease) 10/2006
1	Aspergillosis 07/2006
1	Toxic Epidermal Necrolysis (Lyell's Syndrome) 07/2006
1	Prostatic Neoplasms (Prostate Cancer) 05/2006
1	Neoplasm Metastasis (Metastasis) 10/2005
1	Motion Sickness (Airsickness) 10/2005
1	Lymphoma (Lymphomas) 04/2005
1	Sarcoma (Soft Tissue Sarcoma) 04/2005
1	Adenocarcinoma 07/2004
1	Thrombosis (Thrombus) 04/2004
1	Venous Thromboembolism 01/2000
1	Hypercalcemia (Milk Alkali Syndrome) 01/2000

Drug/Important Bio-Agent (IBA)

9	vinorelbine (Navelbine)FDA LinkGeneric 12/2007 - 01/2000
8	Fluorouracil (Carac)FDA LinkGeneric 07/2004 - 01/2000
7	Cisplatin (Platino)FDA LinkGeneric 05/2004 - 01/2000
6	docetaxel (Taxotere)FDA Link 09/2006 - 03/2000
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2006 - 04/2000
4	Tamoxifen FDA LinkGeneric 10/2005 - 04/2000
3	HormonesIBA 05/2007 - 07/2005
3	Methotrexate (Mexate)FDA LinkGeneric 02/2006 - 04/2000
2	AnthracyclinesIBA 08/2008 - 10/2005
2	DiphosphonatesIBA 01/2008 - 10/2006
2	trastuzumab (Herceptin)FDA Link 12/2007 - 10/2005
2	capecitabine (Xeloda)FDA Link 02/2006 - 12/2004
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2005 - 01/2002
2	CMF regimenIBA 05/2005 - 06/2002
2	gemcitabine FDA Link 02/2001 - 07/2000
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2001 - 07/2000
2	TaxoidsIBA 08/2000 - 06/2000
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 09/2007
1	letrozole (Femara)FDA Link 09/2007
1	Alkaline PhosphataseIBA 04/2007
1	anastrozole (Arimidex)FDA Link 01/2007
1	Aromatase InhibitorsIBA 01/2007
1	fulvestrant (Faslodex)FDA Link 01/2007
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2006
1	voriconazole (Vfend)FDA Link 07/2006
1	VaccinesIBA 05/2006
1	Thalidomide (Thalomid)FDA Link 02/2006
1	Transforming Growth Factor beta (TGF-beta)IBA 09/2005
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 09/2005
1	Steroid Receptors (Steroid Receptor)IBA 07/2005
1	Prothrombin (Factor II)IBA 04/2004
1	factor V LeidenIBA 04/2004
1	Epirubicin (Ellence)FDA LinkGeneric 03/2001
1	Estrogens (Estrogen)FDA Link 08/2000
1	Progesterone Receptors (Progesterone Receptor)IBA 08/2000
1	ViFuP protocolIBA 01/2000
1	Parathyroid Hormone-Related ProteinIBA 01/2000

Therapy/Procedure

16	Drug Therapy (Chemotherapy) 07/2008 - 01/2000
4	Adjuvant Chemotherapy 01/2008 - 02/2000
1	Combination Drug Therapy (Combination Chemotherapy) 07/2001